Xilio Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | |
|---|---|---|---|
| | | XILIO THERAPEUTICS, INC. | |
| | | | |
| Date: March 11, 2025 | | By: | /s/ René Russo |
| | | | René Russo |
| | | | President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | | | | |
|---|---|---|---|---|---|
| Signature | | Title | | | Date |
| | | | | | |
| /s/ René Russo | | President, Chief Executive Officer and Director | | | March 11, 2025 |
| René Russo | | (Principal Executive Officer) | | | |
| | | | | | |
| /s/ Christopher Frankenfield | | Chief Financial Officer and Chief Operating Officer | | | March 11, 2025 |
| Christopher Frankenfield | | (Principal Financial Officer) | | | |
| | | | | | |
| /s/ Kevin Brennan | | Senior Vice President, Finance and Accounting | | | March 11, 2025 |
| Kevin Brennan | | (Principal Accounting Officer) | | | |
| | | | | | |
| /s/ Paul J. Clancy | | Chair of the Board | | | March 11, 2025 |
| Paul J. Clancy | | | | | |
| | | | | | |
| /s/ Sara M. Bonstein | | Director | | | March 11, 2025 |
| Sara M. Bonstein | | | | | |
| | | | | | |
| /s/ Aoife Brennan | | Director | | | March 11, 2025 |
| Aoife Brennan | | | | | |
| | | | | | |
| /s/ Daniel Curran | | Director | | | March 11, 2025 |
| Daniel Curran | | | | | |
| | | | | | |
| /s/ Robert Ross | | Director | | | March 11, 2025 |
| Robert Ross | | | | | |
| | | | | | |
| /s/ Christina Rossi | | Director | | | March 11, 2025 |
| Christina Rossi | | | | | |
| | | | | | |
| /s/ James Shannon | | Director | | | March 11, 2025 |
| James Shannon/s/ Yuan Xu | | Director | | | March 11, 2025 |
| Yuan Xu | | | | | |
Xilio Therapeutics, Inc.
Index to Consolidated Financial Statements
| Report of Independent Registered Public Accounting Firm (PCAOB ID 42) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss | F-4 |
| Consolidated Statements of Stockholders’ Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.